Summary This year’s virtual version of the European Society for Medical Oncology (ESMO) presidential sessions included three “late breaking” non-small cell lung cancer (NSCLC) abstracts, discussing strategies adjuvant therapy localized disease and up-front treatment advanced anaplastic lymphoma kinase(ALK)-positive cancer.

Dichloroacetate (DCA) as a small, cheap and available anticancer agent, is a pyruvate mimetic compound that stimulates the activity of pyruvate dehydrogenase (PDH) enzyme through inhibition of pyruvate dehydrogenase kinases (PDHK1-4). DCA turns on programed cell death (apoptosis) which suppressed in tumor cells and therefore inhibits tumor growth. DCA also interferes with the glucose uses of ca...

Lung cancer remains the leading cause of cancer-related death worldwide. The advent immune checkpoint inhibitors has led to a paradigm shift in treatment metastatic non-small cell and small lung cancer. However, despite prolonged overall survival, only minority patients derive clinical benefit from these treatments suggesting that full anti-tumoral potential system is not being harnessed yet. O...

Ferroptosis therapy gradually becomes a new strategy for the treatment of non-small cell lung cancer (NSCLC) because its active iron metabolism. Because hypoxic microenvironment in NSCLC inhibits ferroptosis heavily,...

Comparison between the first-line and second-line immunotherapy drugs in progression-free survival overall advanced non-small cell lung cancer: a systematic review meta-analysis of randomized controlled trials

Background: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC). Chemotherapy resistance main cause chemotherapy failure. Cullin7 (Cul7) highly expressed in LUAD and associated with poor prognosis. Moreover, Cul7 abnormally overexpressed docetaxel-resistant cells. Therefore, further exploration role molecular mechanism docetaxel necessary.